|
Group
|
Cell cycle distribution (%)
|
|---|
|
G0/G1
|
S
|
G2/M
|
|---|
|
H1975 cells
| | | |
|
Control
|
60.3 ± 3.6
|
31.5 ± 4.8
|
8.2 ± 5.5
|
|
BKM120
|
78.4 ± 3.5*
|
18.9 ± 8.4
|
2.7 ± 1.8
|
|
MEK162
|
72.6 ± 7.7*
|
21.1 ± 6.8
|
6.3 ± 2.3
|
|
BKM120 ± MEK162
|
85.7 ± 5.5**##@@
|
10.6 ± 2.1
|
3.7 ± 2.4
|
|
H460 cells
| | | |
|
Control
|
55.9 ± 4.6
|
33.5 ± 4.8
|
10.6 ± 5.9
|
|
BKM120
|
72.4 ± 2.5*▲
|
24.9 ± 2.4
|
2.7 ± 1.1
|
|
MEK162
|
74.6 ± 5.4*▲
|
20.3 ± 6.8
|
5.1 ± 1.4
|
|
BKM120 ± MEK162
|
91.8 ± 6.9**##@@▲
|
6.6 ± 2.1
|
1.6 ± 0.8
|
|
A549 cells
| | | |
|
Control
|
62.8 + 3.5
|
26.5 + 6.8
|
10.7 + 5.1
|
|
BKM120
|
76.4 + 5.5*&
|
18.9 + 8.4
|
4.7 + 4.8
|
|
MEK162
|
77.9 + 6.7*&
|
15.8 + 3.8
|
6.3 + 2.9
|
|
BKM120 + MEK162
|
88.6 + 6.6**##@@&
|
9.2 + 3.8
|
2.2 + 1.2
|
- H1975, H460, and A549 cells were treated with 1 μM MEK162 (MEK inhibitor) or 5 μM BKM120 (PI3K inhibitor) alone or in combination for 48 h. Control cells were treated with DMSO (0.05%). After treatment, the cells were stained with propidium iodide (PI) and analyzed by flow cytometry. Each value represents mean ± standard deviation (SD) obtained from three independent experiments
- *P < 0.05 vs. Control; #P < 0.05 vs. BKM120; @P < 0.05 vs. MEK162; ▲P < 0.05 vs. H1975 cells; &P < 0.05 vs. H460 cells under the same cell cycle phase and the same drug treatment
